An observational study in Proteinuria, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by University of Miami · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Proteinuria with a site in United States — 20 open to participants now, 25 under way, 9 of them phase 3. Proteinuria · United States.
Among the 126 studies in Proteinuria with a site in United States, this one is the 15th largest by planned enrollment of the 29 observational ones that give a count, is one of 3 that started in 2008, is one of 29 observational ones, reaches primary completion later than 9 of the 23 other live ones, and was the 38th registered.
330 studies on the registry are indexed under Proteinuria; 45 are open to participants now.
Browse Proteinuria studies →20 of the 126 studies in Proteinuria with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, Israel
Ages 18+
Geisinger Clinic · Sites in United States
Ages 18+
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 18–115
Brigham and Women's Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Proteinuria studies recruiting now, 13 (39%) set no upper age limit and 16 (48%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.
This study: Up to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 39 · Phase 3 19 · Phase 4 14
First in 1989; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 119 across 67 observational studies indexed under Proteinuria.
Median enrollment 30 across the 97 interventional studies, 100 across the 29 observational. Of the 83 that completed or were terminated, 39 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 126 have an industry lead sponsor. The 10 most frequent:
University of Miami is the lead sponsor of 843 studies on the registry; 166 are open to participants now.
Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.
University of Miami has 1 study filed under Proteinuria — fewer than ten, so there is no comparison to draw.
9 of the studies in Proteinuria with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04817618Phase 3Novartis PharmaceuticalsStudy of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. | 2027-01-29 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT05970341University of Texas at AustinKidney Health: Eat Well, Live Well | 2026-11-30 |
| NCT04752293Wake Forest University Health SciencesPediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE) | 2026-12 |
| NCT07224776Brigham and Women's HospitalSparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria | 2026-12-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 126 studies in Proteinuria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with focal segmental glomerulosclerosis (FSGS) who progress rapidly to end stage renal disease (ESRD) are at highest risk for development of recurrence of proteinuria following kidney transplantation. This study will look at serum specimens pre and post transplant, as well as kidney transplant specimens pre and post reperfusion to identify where the defects has occured that results in recurrence of proteinuria in a given kidney transplant.
This study will retrospectively review patient's medical records for protein in the urine, blood creatinine and kidney biopsy results. Also character of the fluid used to flush the kidney before transplant will be analyzed.
Pediatric population up to the age of 25 years old, with biopsy diagnosed of FSGS (focal segmental glomerulosclerosis).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Explain mechanisms behind the development of proteinuria in patients immediately after receiving a kidney transplant
chart review
Time frame: through study completion, an average of 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2008 (actual). Primary completion is estimated for Nov 2027, 237 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Nov 2026 → Nov 2027 and completion Nov 2026 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.